HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reaffirmed a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $47 to $51.

December 21, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Immunovant and raises the price target from $47 to $51.
The reaffirmation of a Buy rating and an increase in the price target typically signal a positive outlook on the company's stock from the analyst's perspective. This can lead to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100